Scancell (LON:SCLP) Trading 13.3% Higher – Should You Buy?

Scancell Holdings plc (LON:SCLP)’s stock price rose 13.3% during mid-day trading on Monday . The stock traded as high as GBX 10.24 ($0.14) and last traded at GBX 9.60 ($0.13). Approximately 5,103,223 shares were traded during trading, an increase of 520% from the average daily volume of 823,542 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Stock Performance

The firm has a market capitalization of £105.90 million, a PE ratio of -15.68 and a beta of 0.35. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The company has a 50-day moving average of GBX 8.51 and a 200 day moving average of GBX 10.85.

Scancell (LON:SCLP) last issued its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) EPS for the quarter. Equities research analysts predict that Scancell Holdings plc will post -2.5361112 EPS for the current year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.